Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rich is rodman you moron.
"But what is the most alarming to us in the 10/18/19 announcement is that the PR went silent on the very important product safety outcomes. From the UEEC clinical protocol, described on its clinicaltrials.gov page we learned about four secondary study outcomes:
Source: clinicaltrials.gov
While the Primary outcome and the Secondary outcome #1 in the UEEC study protocol are efficacy related, the Secondary #2, #3, and #4 outcomes are all safety outcomes and are of critical importance for FDA approval. The October 18th PR only addresses success of the Primary outcome and Secondary outcome #1. The PR didn't say if the study has shown a non-inferiority or superiority of HemoStyp vs Surgicel in the secondary outcomes #2-4. The history of UEEC only disclosing positive news makes us believe that the omission of results relevant to outcomes #2-4 could have been on purpose, because the clinical study likely showed the inferior performance of HemoStyp vs Surgicel in these outcome measures.
The statistician was very specific to claim non-inferiority and superiority of HemoStyp only in the initial hemostasis after application of HemoStyp to the wound. It is silent on what has happened after the initial hemostasis was achieved.
HemoStyp, according to UEEC, quickly dissolves in an aqueous environment due to its unique degradation properties. We can find this on the company’s website.
From UEEC’s product testing page:
The data obtained during analysis of sample UHP Box of 2” x 2” Pouches indicates the material begins to dissolve in water within one minute. The sample is completely dissolved within 24 hours. Not enough material remains for analysis at the 24 hour time point.
If HemoStyp dissolves too soon, the surgical wound would start bleeding again, and this would be a very serious safety issue.
Imagine a major disaster when bleeding re-occurs after the surgeon has already closed the outmost patient skin layer! The outcomes 2-4 directly address this key safety concern, describing in quantitative terms how well the initially achieved hemostasis is maintained during the surgery. Outcome 4 is about the failure of initial hemostasis, as measured in reoperations, during the one month after surgery. It seems to us that a hemostatic agent that is quick to achieve initial hemostasis, but rapidly dissolves and may frequently fail later resulting in recurrence of bleeding, is a major health hazard. Why would the FDA approve HemoStyp, if it indeed fails to maintain hemostasis, knowing that Surgicel is already a reasonably effective and safe FDA approved product?
From all these observations, we conclude that the clinical study of HemoStyp versus Surgicel was likely a failure. However, if and when its PMA application" gets rejected, we doubt that shareholders will hear about it. We expect it will be just like when UEEC applied for PMA approval for Class III in late 2017, there will just not be any updates, like it never happened.""
I don't know. To be honest I haven't spent much time analyzing this one (although I have followed it for quite some time). It may also be insiders, with a good association with him, dumping. But I'm noticing plenty of new people pouring in daily. They are buying and the price is not going up. That worries me. A lot of money is pouring in now and yet it is simultaneously being pulled out. The biggest red flag, at least to me, is the tweet frequency. That isn't normal. That suggests watching the price is his main concern when it should be the actual business. Is he overextended at the very least? Usually the stock price will take care of itself as the business succeeds. Once a month is plenty of updating.
He says a major PR is coming. Hopefully, the selling was to fund something. On the other hand, he could be more specific. I'm sitting this out. I see too much risk. My mind is made up on that. But I'm hardly certain this is a scam. It just doesn't look too good. The price has, about tripled, and yet the material news always gets delayed. I'm not certain this is a scam. I honestly hope my instincts are wrong and you guys make out.
Rodman, you've got incredibly serious Daddy issues. All you do is keep mentioning parents. And you're an adult still infatuated by parents? This doesn't even begin to touch upon how intellectually challenged you are. Additionally you are sneaky, dishonest, and have zero sense of ethical behavior. I'm sure as a child, going to Grandma's so you could rifle her purse and leave her penniless, gave you a feeling of joy. You are so limited in your self-awareness, you don't even know enough to realize what an embarrassment you are to everyone who has the misfortune of associating with you. You are a basket case of lack of emotional development and maturity. Go ahead keep mentioning the Daddy you can't get out of your head. That, in itself, is obviously a challenge you will never overcome. Now carry on with your tantrum over not stealing enough of other people's money,
Hey, there are several posters here who are real Duesies. I have to go real slow and simple for their sake (not yours) or they get overwhelmed, bewildered and upset.
Good question. All I know is the obvious. Mr. Blagman needed funding. Enter mwwc. Maybe a third party link up? This sounds like Mr. Blagman's cover letter. Maybe he sent it to mwwc:
"I have spent the past 15 years recreating a new media content business model- a revelation of new ideas and quantifiable results based on new heavily researched algorithms for digital and linear media.
I plan to bring these advances to my clients as well as introduce a new global media network based on quantifiable results for advertisers and digital brands.
My full focus is on the future (which is NOW) of media and how to deliver the specific assets that brands, advertisers, sponsors, and ultimately the consumer requires and demand.
Among other tasks, I distribute TV programming globally targeting media bundling within an unparalleled model. I have built an interesting process with key partners and an unwired network of digital portals in 40+ countries that deliver audited views that have crossed the multi-billion mark. I seek solutions to solving the global media puzzle we are surrounded by. A key and vital approach is securing a number of rock-solid revenue streams to support new media, and new concepts, leaving little to chance.
I speak to top execs all around the world and hear the real story. Netflix is NOT the answer to everything. If you live by headlines you will miss the real story.
I have proven and unprecedented experience in North American and International TV Content, airtime acquisition, syndication, and TV commercial sales and buying. I also maintain a massive database of executives throughout the TV and Advertising industries.
After leaving Disney in 1994, I created three TV networks in Eastern Europe. In the late 90’s I took my company public, and purchased the former Williams Media.
In the 2000’s I mastered media buying and programming for online poker. With great clients like Party Poker and Full Tilt Poker, I was able to hit 4000 annual hours of programming throughout the world. Because it was so lucrative to the online poker companies and TV stations and networks all around the world, my relationships only strengthened. Certainly, my biggest hit was Poker After Dark (airing on 20 TV networks globally including NBC in the USA).
I am in a unique position to help you and your company…embracing digital streaming distribution and premiere TV Network clearances, I know how to produce a proper ROI.
Let's take on the world together!"
I'm guessing the guy doing the frequent tweets is dumping. Why else would he tweet so frequently? Otherwise, he'd just wait until he makes an official statement.
"How about 0015 by the end of the day"
Bullshit. There will be one excuse after another as you scam suckers. What is this? The fifth time you clowns have run the PMA bait & switch shell game? Now you are already stretching out this leg of the scam to Halloween. ROTFLMAO. You damn well know there will never be FDA approval of a couple of crates of the cheap Chinese gauze Beplate bought a decade ago. It's hilarious watching a group of adults play pretend this a real company.
I try to be fair and honest. If I am not, I will just screw myself over along with other people. The trouble with bullshitters is eventually they start to believe their own bullshit is reality. I do not want to answer the latter question. Sometimes, and it is very apparent in these volatile penny stocks, people react very emotionally. Incredibly, my PM's are filled with many dozens of threats. People tend to sell and buy and react emotionally. And this can be manipulated. I am very interested in how this will play out. Great emphasis on the word interesting. I only wish I knew the details of how this show will distribute. This show has, as I have said all along, enormous potential for success. Will it achieve that? Will it achieve that out of the gate? Will it achieve that after a slow start? Will it sputter? What it start in all markets simultaneously or roll out in select markets initially? So many questions and so little answers right now. Anything can happen. Stay tuned (pun intended).
jrockents, thanks for these updates you have given us all along. They have been enlightening and provided insight when we would otherwise not have heard anything.
Thanks ITYS. You seem very honest in what you have said and without agenda. I will add this. Marketing Worldwide had been eerily silent. And there are updates they could have given. I am referring to honest material and not pumping bullshit in saying that. Mr. Blagman has been the only source of information for the past year. It almost seems they are purposely not helping the price rise. So I agree except, in this case, Hollywood After Dark is a real entity with potential. What little news there has been, has been real. Something is going to happen here. In a sense, the silence is deafening and getting worse. I am very interested in how this plays out. I would not be involved if HAD were a scam. The filings here are on the up and up anyway. I am not seeing a single sign of illegality in the filings.
I took surf's and angel's suggestions and reached out for information. I do not know any details, let alone the details with any certainty, so I make no suggestion what anyone should do. Sell, buy, or hold at your own discretion. Post anything you want to. The short term price fluctuation will not effect me. I know nothing of what is going on at mwwc other than observation like the rest of you. I responded to ITYS in my previous post about what I thought honestly. Regarding, Hollywood After Dark; it is silent right now. But I will say this with a good degree of certainty. It was filmed. Anyone can contact the Bourbon Room and speak to employees to verify that. It makes no sense to have filmed it and not come out with the show. Put yourself in Mr. Blagman's shoes. Would you go through all that and do anything at all? I have no idea, what fashion it will be distributed. I await that news and details myself. But it will be distributed somehow. To go through the trouble of producing the show, of an entire night, and not do something with it makes no sense. Again, I have no idea of how so I make no further claim than that. Make of that what you will. I actually know a little more than I am saying (not much more) but I will be accused by the negative elements of bullshitting about anything positive and I will be hated by shareholders for anything negative. So I'll largely keep my mouth shut. There are people very close to this, and in a better position to know, that are on standby and silent awaiting details too. Good luck to everyone whatever you decide to do.
He is doing a piss poor job of pumping it, ITYS, if that is the case. Dead silence here from everyone concerned. I'm not seeing much evidence of organized selling. If you are asking me for an honest, educated, guess; I think everyone is trying to figure out what their next move is right now. And I am not getting any indication of what that might be. The price here is as about as low as it gets and no one, at present, is doing anything to move it. That doesn't quite fit the usual mode of a scam. Just my take, but I do not think Ted Ralston is doing anything at present to benefit himself or anyone else. And I could make that statement about anyone involved presently.
"Nobody here is selling"
"You have simply pasted what a simpleton wants to see"
"Imagine a major disaster when bleeding re-occurs after the surgeon has already closed the outmost patient skin layer! "
https://seekingalpha.com/article/4300303-united-health-products-press-releases-cannot-be-taken-face-value
What a foolish scam this is fishing for suckers to lay their money down. What a joke to think the cheapest Chinese bandage money can buy will ever be used as a surgical bandage. Who could be possibly be insipid enough to believe this u-haul dealer in the desert headquartered company is producing a surgical bandage.
Sleezy boiler room fraud about cheap Chinese gauze that is totally non-functional even over the counter. This pathological, sociopathic bullshit you spew does not even belong on ihub.
https://www.sec.gov/files/litigation/complaints/2022/comp25413.pdf
This con artist outfit is such a sham, headquarters, as listed on their website, is a u-haul dealer in the desert.
The CEO of this stock scam is actually a stock broker
https://brokercheck.finra.org/individual/summary/4231884
Evidently he does not even want his clients to know he manipulates this stock scam Ponzi scheme:
https://www.butlercap.com/our-team-2
"But what is the most alarming to us in the 10/18/19 announcement is that the PR went silent on the very important product safety outcomes. From the UEEC clinical protocol, described on its clinicaltrials.gov page we learned about four secondary study outcomes:
Source: clinicaltrials.gov
While the Primary outcome and the Secondary outcome #1 in the UEEC study protocol are efficacy related, the Secondary #2, #3, and #4 outcomes are all safety outcomes and are of critical importance for FDA approval. The October 18th PR only addresses success of the Primary outcome and Secondary outcome #1. The PR didn't say if the study has shown a non-inferiority or superiority of HemoStyp vs Surgicel in the secondary outcomes #2-4. The history of UEEC only disclosing positive news makes us believe that the omission of results relevant to outcomes #2-4 could have been on purpose, because the clinical study likely showed the inferior performance of HemoStyp vs Surgicel in these outcome measures.
The statistician was very specific to claim non-inferiority and superiority of HemoStyp only in the initial hemostasis after application of HemoStyp to the wound. It is silent on what has happened after the initial hemostasis was achieved.
HemoStyp, according to UEEC, quickly dissolves in an aqueous environment due to its unique degradation properties. We can find this on the company’s website.
From UEEC’s product testing page:
The data obtained during analysis of sample UHP Box of 2” x 2” Pouches indicates the material begins to dissolve in water within one minute. The sample is completely dissolved within 24 hours. Not enough material remains for analysis at the 24 hour time point.
If HemoStyp dissolves too soon, the surgical wound would start bleeding again, and this would be a very serious safety issue.
Imagine a major disaster when bleeding re-occurs after the surgeon has already closed the outmost patient skin layer! The outcomes 2-4 directly address this key safety concern, describing in quantitative terms how well the initially achieved hemostasis is maintained during the surgery. Outcome 4 is about the failure of initial hemostasis, as measured in reoperations, during the one month after surgery. It seems to us that a hemostatic agent that is quick to achieve initial hemostasis, but rapidly dissolves and may frequently fail later resulting in recurrence of bleeding, is a major health hazard. Why would the FDA approve HemoStyp, if it indeed fails to maintain hemostasis, knowing that Surgicel is already a reasonably effective and safe FDA approved product?
From all these observations, we conclude that the clinical study of HemoStyp versus Surgicel was likely a failure. However, if and when its PMA application" gets rejected, we doubt that shareholders will hear about it. We expect it will be just like when UEEC applied for PMA approval for Class III in late 2017, there will just not be any updates, like it never happened.""
Sorry. When I put it in comic book form a small portion might penetrate into than cranium (sorry again-big word, let's call it a brain pan) of yours.
You are a paid hack who fabricates petty bullshit. There is no other reason to explain the absurdity of your posts.
"May see 0012-0013 by the end of the day!"
"we doubt that shareholders will hear about it. We expect it will be just like when UEEC applied for PMA approval for Class III in late 2017, there will just not be any updates, like it never happened."
In any event, I doubt he is holding shares. He is more the type who dupes others.
When he has ever posted anything accurate and relevant? Thanking Lamstein, in this instance, was as strong a clue as can be that it would not be both.
Can you state what the actual financial impact will be?
How many weeks has it been put off?
On pure bullshit and hype.
Very telling of an obvious scam when intimidation and insulting attacks are substituted for rational, logical, and thoughtful substance. Who are the clowns and dbags forcefully suckering people out ot their hard earned money?
Repeat this again for the dbags in the back! I thought foreskin sealshin was the biggest dbag but this shoondale may be the biggest clown on the board yet.
Posters with few posts, using expressiveness_and_grammar similar to long term posters are beyond suspect.
Shodburrito
Level Icon
Followers 0
Posts 3
Boards Moderated 0
Alias Born 09/12/2023
Okay, I'm done being nice. Stop blatantly scamming people.
Reguritated bullshit. PMA bait & switches since 2017...
https://www.otcmarkets.com/filing/html?id=12414685&guid=4td-kaJ6H_M4B3h#UEEC_EX991_HTM
"FDA Selects HemoStyp ® for CtQ Pilot Program
Henderson, Nevada – December 4, 2017 –United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).
The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the postmarket inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a postmarket inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner. This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html)
Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review
About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.
More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.
This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.
The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA’s analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors.
In simple terms, the review identified that an investment in quality has long-term payoffs."
Again, it was filmed in August. It did not appear on the BG website until September. By my math, that is 7 months tops. Maybe by your math it comes out to a year.
It has not changed for a year. It could be there forever. Meaningless until we heart something other than a web page.
You must not know much about his reputation. He's never made even a penny in revenue for any company.
Fully funded? He didn't do anything but sell shares
But what is the most alarming to us in the 10/18/19 announcement is that the PR went silent on the very important product safety outcomes. From the UEEC clinical protocol, described on its clinicaltrials.gov page we learned about four secondary study outcomes:
Source: clinicaltrials.gov
While the Primary outcome and the Secondary outcome #1 in the UEEC study protocol are efficacy related, the Secondary #2, #3, and #4 outcomes are all safety outcomes and are of critical importance for FDA approval. The October 18th PR only addresses success of the Primary outcome and Secondary outcome #1. The PR didn't say if the study has shown a non-inferiority or superiority of HemoStyp vs Surgicel in the secondary outcomes #2-4. The history of UEEC only disclosing positive news makes us believe that the omission of results relevant to outcomes #2-4 could have been on purpose, because the clinical study likely showed the inferior performance of HemoStyp vs Surgicel in these outcome measures.
The statistician was very specific to claim non-inferiority and superiority of HemoStyp only in the initial hemostasis after application of HemoStyp to the wound. It is silent on what has happened after the initial hemostasis was achieved.
HemoStyp, according to UEEC, quickly dissolves in an aqueous environment due to its unique degradation properties. We can find this on the company’s website.
From UEEC’s product testing page:
The data obtained during analysis of sample UHP Box of 2” x 2” Pouches indicates the material begins to dissolve in water within one minute. The sample is completely dissolved within 24 hours. Not enough material remains for analysis at the 24 hour time point.
If HemoStyp dissolves too soon, the surgical wound would start bleeding again, and this would be a very serious safety issue.
Imagine a major disaster when bleeding re-occurs after the surgeon has already closed the outmost patient skin layer! The outcomes 2-4 directly address this key safety concern, describing in quantitative terms how well the initially achieved hemostasis is maintained during the surgery. Outcome 4 is about the failure of initial hemostasis, as measured in reoperations, during the one month after surgery. It seems to us that a hemostatic agent that is quick to achieve initial hemostasis, but rapidly dissolves and may frequently fail later resulting in recurrence of bleeding, is a major health hazard. Why would the FDA approve HemoStyp, if it indeed fails to maintain hemostasis, knowing that Surgicel is already a reasonably effective and safe FDA approved product?
From all these observations, we conclude that the clinical study of HemoStyp versus Surgicel was likely a failure. However, if and when its PMA application" gets rejected, we doubt that shareholders will hear about it. We expect it will be just like when UEEC applied for PMA approval for Class III in late 2017, there will just not be any updates, like it never happened."
Are you serious or bullshitting around? I think you better look up the definition of slander. Below your quote is mine. Where is the slander? I will stand by what I said. There is more hype than necessary for a deal of substance from the SAPX end. Let's see what happens. I asked several times, in other posts, what could possible go wrong? Let us see this play out now. I'm especially interested to see the financial impact this will have on Seven Arts, in the end, if this deal goes through. Hey, I hope you guys make out. I just still have my strong doubts.
To be clear, Are you suggesting that mega billion dollar LionsGate , now named in the 8-K filed deal with SAPX, is not "Legitimate"?
I would not want to miss understand you slanderous claim.
No legitimate business puts out tweets this frequently with zero substance behind them. They usually keep their mouths shut until something of substance is going to be announced. It wreaks of someone trying to prop up the share price artificially. It becomes clearer by the tweet or time. If there was anything to announce; it would be announced. Instead, there is one excuse after another with one delay after another. I shouldn't have to explain this to anyone with "sense" as you call them.
OK angels, how do you figure Jason is sabotaging HAD? The only thing he could have done is withhold financing. And that was not the case. HAD was fully funded. Not everything is Jason's fault. The last time I saw anything you could misconstrue as a misstep was the failed crypto endeavor. Did you forsee the crypto collapse? Jason did not. In my case, I cannot fault him because I did not see it either. How do you figure Jason is responsible for lack of network programming? That seems to me to be Blagman's responsibility. What are you seeing here?
Drilling for oil? They should have been drilling a hole in your skull to proceed with the lobotomy.